Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
125.1 USD | +0.10% | +4.24% | +1.50% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.50% | 3.11B | B | ||
+17.59% | 66.51B | A- | ||
+0.84% | 48.47B | A- | ||
+17.11% | 41.43B | B+ | ||
+22.33% | 27.19B | A- | ||
+11.45% | 19.82B | C+ | ||
+5.08% | 18.15B | B+ | ||
-21.31% | 15.98B | A- | ||
+4.38% | 15.53B | B+ | ||
-9.70% | 15.46B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IOSP Stock
- Ratings Innospec Inc.